Thyroid hormones, mitochondrial bioenergetics and lipid handling

Area of Science:

• Endocrinology
• Metabolic research
• Mitochondrial function

Background:

• Thyroid hormones (T4, T3) traditionally viewed as primary metabolic regulators.
• Mitochondria are key organelles for thyroid hormone action.
• Obesity, dyslipidemia, and cardiovascular diseases are major global health concerns.

Purpose of the Study:

• To review recent advancements in understanding thyroid hormone metabolites and analogues.
• To highlight their potential therapeutic applications in metabolic disorders.
• To focus on mitochondrial mechanisms of action.

Main Methods:

• Review of recent scientific literature.
• Analysis of studies on natural metabolites (e.g., T2) and synthetic analogues (e.g., GC-1, KB2115).
• Focus on mitochondrial uncoupling and modulation.

Main Results:

• Thyroid hormone metabolites and analogues demonstrate significant metabolic benefits.
• 3,5-diiodothyronine (T2) effectively reduces adiposity, dyslipidemia, and hepatic steatosis without adverse effects.
• Synthetic analogues like GC-1 and KB2115 exhibit lipid-lowering and anti-atherogenic properties.

Conclusions:

• Emerging thyroid hormone derivatives show therapeutic potential for metabolic diseases.
• Compounds like T2, GC-1, and KB2115 are advancing to clinical trials.
• These agents may significantly impact endocrinology and the management of diabetes and dyslipidemias.